Litcius/Paper detail

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Elias Jabbour, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, William G. Wierda, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Koji Sasaki, Tapan M. Kadia, Joseph D. Khoury, Sa A. Wang, Fadi Haddad, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

2023The Lancet Haematology104 citationsDOIOpen Access PDF

Topics & Concepts

BlinatumomabMedicineAcute lymphocytic leukemiaInternal medicineVincristinePrednisoneAdverse effectGastroenterologyChemotherapyPediatricsLeukemiaCyclophosphamideLymphoblastic LeukemiaChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia researchCAR-T cell therapy research